SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

29 Oct 2024 Evaluate
The sales slipped to Rs. 25.73 millions for the September 2024 quarter as against Rs. 30.60 millions during the year-ago period.The Net Loss for the quarter ended September 2024 is Rs. -110.72 millions as compared to Net Profit of Rs. 27.55 millions of corresponding quarter ended September 2023 Operating profit Margin for the quarter ended September 2024 improved to -96.01% as compared to -29.34% of corresponding quarter ended September 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 25.73 30.60 -15.92 35.79 68.57 -47.81 116.93 135.39 -13.63
Other Income 40.35 51.42 -21.53 79.66 107.82 -26.12 211.30 84.49 150.09
PBIDT -96.01 -29.34 227.23 -157.58 -40.89 285.38 -98.07 -192.95 -49.17
Interest 0.16 0.42 -61.90 0.39 0.93 -58.06 1.58 2.89 -45.33
PBDT -96.17 44.81 -314.62 -157.97 32.75 -582.35 -25.08 -135.84 -81.54
Depreciation 14.55 17.26 -15.70 29.41 33.90 -13.24 65.02 65.43 -0.63
PBT -110.72 27.55 -501.89 -187.38 -1.15 16193.91 -90.10 -201.27 -55.23
TAX 0.00 0.00 0.00 0.00 0.00 0.00 -10.02 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -110.72 27.55 -501.89 -187.38 -1.15 16193.91 -80.08 -201.27 -60.21
Equity 218.07 218.07 0.00 218.07 218.07 0.00 218.07 218.07 0.00
PBIDTM(%) -373.14 -95.88 289.17 -440.29 -59.63 638.34 -83.87 -142.51 -41.15

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×